
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
The Side Effects of Lenvatinib
Author(s)Lori J. Wirth, MD
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the side effects of lenvatinib in patients with thyroid cancer.
Advertisement
Articles in this issue
about 11 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerabout 11 years ago
Sequencing Sorafenib and Lenvatinib in Thyroid Cancerabout 11 years ago
Immune Checkpoint Inhibitors for Head and Neck Cancersabout 11 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5






































